Effect of urokinase‑type plasminogen activator system in gastric cancer with peritoneal metastasis

Ding,Youcheng; Zhang,Hui; Lu,Aiguo; Zhou,Zhuqing; Zhong,Mingan; Shen,Dongwei; Wang,Xujing; Zhu,Zhenggang

doi:10.3892/ol.2016.4498

Effect of urokinase‑type plasminogen activator system in gastric cancer with peritoneal metastasis

Authors:
- Youcheng Ding
- Hui Zhang
- Aiguo Lu
- Zhuqing Zhou
- Mingan Zhong
- Dongwei Shen
- Xujing Wang
- Zhenggang Zhu
View Affiliations

Affiliations: Department of General Surgery, Shanghai East Hospital Affiliated to Tongji University, Shanghai 200120, P.R. China, Department of Gastroenterological Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China
Published online on: April 26, 2016 https://doi.org/10.3892/ol.2016.4498
Pages: 4208-4216

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanisms of the uPA system in gastric cancer with peritoneal metastasis. Expression of uPA, uPA receptor (uPAR) and plasminogen activator inhibitor‑1 (PAI‑1) in four gastric cell lines (AGS, SGC7901, MKN45 and MKN28) was measured by semiquantitative reverse transcription polymerase chain reaction, enzyme‑linked immunosorbent assay and western blotting. uPA activity was detected using a uPA activity kit. Peritoneal implantation models of rats were established by injecting four gastric cancer cell lines for the selection of the cancer cells with a high planting potential. Biological behaviors, including adhesion, migration and invasion, were determined using a methyl thiazolyl tetrazolium assay. Expression of the uPA system was observed to be highest in the SGC7901 cells among the four gastric cell lines. uPA activity was observed to be highest in the MKN45 cells and lowest in the AGS cells. Furthermore, peritoneal implantation analysis demonstrated that no peritoneal tumors were identified in the AGS cells, whilst the tumor masses observed in the SGC7901 and MKN45 cells were of different sizes. The survival times of the rats injected with the MKN28 and SGC7901 cells were longer than those of the rats injected with the MKN45 cells. Antibodies for uPA, uPAR and PAI‑1 in the uPA system had the ability to inhibit the adhesion, migration and invasion of peritoneal metastasis in the gastric cancer cells. The results of the present study demonstrated that the uPA system was positively associated with peritoneal metastasis in gastric cancer.

View Figures

View References

1	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
2	Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, et al: Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer. 18:288–296. 2015. View Article : Google Scholar : PubMed/NCBI
3	Fujii S, Kitayama J, Kaisaki S, Sasaki S, Seto Y, Tominaga O, Tsuno N, Umetani N, Yokota H, Kitamura K, et al: Carcinoembryonic antigen mRNA in abdominal cavity as a useful predictor of peritoneal recurrence of gastric cancer with serosal exposure. J Exp Clin Cancer Res. 21:547–553. 2002.PubMed/NCBI
4	Zhao P, Lu Y, Jiang X and Li X: Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102:1107–1111. 2011. View Article : Google Scholar : PubMed/NCBI
5	Thompson EW, Newgreen DF and Tarin D: Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cho RW and Clarke MF: Recent advances in cancer stem cells. Curr Opin Genet Dev. 18:48–53. 2008. View Article : Google Scholar : PubMed/NCBI
7	John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI
8	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
9	Fenoglio-Preiser C, Carneiro F, Correa P, Guildford P, Lambert R, Megraud F, Muñoz N, Powell SM, Rugge M, Sasako M, et al: Gastric carcinoma. In: World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. IARC Press. (Lyon). 35–52. 2000.
10	Crippa MP: Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 39:690–694. 2007. View Article : Google Scholar : PubMed/NCBI
11	Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 94:116–128. 2002. View Article : Google Scholar : PubMed/NCBI
12	Pulukuri SMK and Rao JS: Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res. 67:6637–6646. 2007. View Article : Google Scholar : PubMed/NCBI
13	Dass K, Ahmad A, Azmi AS, Sarkar SH and Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 34:122–136. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kaneko T, Konno H, Baba M, Tanaka T and Nakamura S: Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci. 94:43–49. 2003. View Article : Google Scholar : PubMed/NCBI
15	Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, et al: Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648–4655. 2003.PubMed/NCBI
16	Champelovier P, Boucard N, Levacher G, Simon A, Seigneurin D and Praloran V: Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: Diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res. 30:301–309. 2002. View Article : Google Scholar : PubMed/NCBI
17	Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG and Bagnato A: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61:8340–8346. 2001.PubMed/NCBI
18	Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T, Kinoshita K, Endo Y, Sugiyama K and Sasaki T: Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res. 7:1647–1653. 2001.PubMed/NCBI
19	Kilkenny C, Browne W, Cuthill IC, Emerson M and Altman DG: NC3Rs Reporting Guidelines Working Group: Animal research Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 160:1577–1579. 2010. View Article : Google Scholar : PubMed/NCBI
20	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
21	Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
23	Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res. 71:277–286. 2011. View Article : Google Scholar : PubMed/NCBI
24	Qiu X, Guo S, Wu H, Chen J and Zhou Q: Identification of Wnt pathway, uPA, PAI-1, MT1-MMP, S100A4 and CXCR4 associated with enhanced metastasis of human large cell lung cancer by DNA microarray. Minerva Med. 103:151–164. 2012.PubMed/NCBI
25	Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J and Ávila MA: Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers (Basel). 3:2444–2461. 2011. View Article : Google Scholar : PubMed/NCBI
26	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
27	Mutsaers SE: The mesothelial cell. Int J Biochem Cell Biol. 36:9–16. 2004. View Article : Google Scholar : PubMed/NCBI
28	Na D, Liu FN, Miao ZF, Du ZM and Xu HM: Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by anti-apoptosis. World J Gastroenterol. 15:570–577. 2009. View Article : Google Scholar : PubMed/NCBI
29	Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M and Rømer J: Plasminogen activation and cancer. Thromb Haemost. 93:676–681. 2005.PubMed/NCBI
30	Mekkawy AH, Morris DL and Pourgholami MH: Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 5:1487–1499. 2009. View Article : Google Scholar : PubMed/NCBI
31	Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A and Patten DY: Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. J Androl. 7:147–158. 2005.
32	Binder BR, Mihaly J and Prager GW: uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost. 97:336–342. 2007.PubMed/NCBI
33	Li XF, Yan PJ and Shao ZM: Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 28:3937–3948. 2009. View Article : Google Scholar : PubMed/NCBI
34	Pluskota E, Soloviev DA and Plow EF: Convergence of the adhesive and fibrinolytic systems: Recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood. 101:1582–1590. 2003. View Article : Google Scholar : PubMed/NCBI
35	Blasi F and Sidenius N: The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 584:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
36	Montuori N, Cosimato V, Rinaldi L, Rea VEA, Alfano D and Ragno P: uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost. 109:309–318. 2013. View Article : Google Scholar : PubMed/NCBI
37	Grove LM, Southern BD, Jin TH, White KE, Paruchuri S, Harel E, Wei Y, Rahaman SO, Gladson CL, Ding Q, et al: Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem. 289:12791–12804. 2014. View Article : Google Scholar : PubMed/NCBI
38	Nowicki TS, Zhao H, Darzynkiewicz Z, Moscatello A, Shin E, Schantz S, Tiwari RK and Geliebter J: Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle. 10:100–107. 2011. View Article : Google Scholar : PubMed/NCBI
39	Sheng S: The urokinase-type plasminogen activator system in prostate cancer metastasis. Prostate Cancer: New Horizons in Research and Treatment. Cher ML, Honn KV and Raz A: Springer. 151–160. 2002.
40	Francis RM, Romeyn CL, Coughlin AM, Nagelkirk PR, Womack CJ and Lemmer JT: Age and aerobic training status effects on plasma and skeletal muscle tPA and PAI-1. Eur J Appl Physiol. 114:1229–1238. 2014. View Article : Google Scholar : PubMed/NCBI
41	Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, et al: uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases. Transl Oncol. 5:98–104. 2012. View Article : Google Scholar : PubMed/NCBI
42	Huber AV, Saleh L, Bauer S, Husslein P and Knöfler M: TNFalpha-mediated induction of PAI-1 restricts invasion of HTR-8/SVneo trophoblast cells. Placenta. 27:127–136. 2006. View Article : Google Scholar : PubMed/NCBI